Data updated: Mar 10, 2026
LATANOPROST
LATANOPROST
Approved 2011-03-22
8
Indications
--
Phase 3 Trials
14
Years on Market
Details
- Status
- None (Tentative Approval)
- First Approved
- 2011-03-22
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION, SOLUTION/DROPS
Companies
PAR PHARM Novartis Apotex SOMERSET GLAND FDC LTD PHARMOBEDIENT EUGIA PHARMA AMRING PHARMS EPIC PHARMA LLC MICRO LABS BAUSCH AND LOMB MANKIND PHARMA
Active Ingredient: LATANOPROST
Website: ↗
LATANOPROST Approval History
Loading approval history...
What LATANOPROST Treats
8 FDA approvalsOriginally approved for its first indication in 2011 . Covers 8 distinct patient populations.
- Other (8)
Other
(8 approvals)- • Approved indication (Mar 2011)
- • Approved indication (Jul 2011)
- • Approved indication (Feb 2013)
- • Approved indication (Apr 2016)
- • Approved indication (Sep 2019)
- • Approved indication (Nov 2024)
- • Approved indication (Apr 2025) New
- • Approved indication (Dec 2025) New
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LATANOPROST FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.